Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270

Blood

Volumn 101, Issue 10, 2003, Pages 3908-3914

  Ding, Zhongren ^b   Kim, Soochong ^b   Dorsam, Robert T ^b   Jin, Jianguo ^b   Kunapuli, Satya P ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLTHIOADENOSINE DIPHOSPHATE; 2',3' O (4 BENZOYLBENZOYL)ADENOSINE 5' TRIPHOSPHATE; ADENOSINE DIPHOSPHATE; ADENYLATE CYCLASE; CLOPIDOGREL; CYSTEINE; CYSTEINE DERIVATIVE; MUTANT PROTEIN; PHOSPHOLIPASE 2Y12 RECEPTOR; PROTEIN SUBUNIT; RECEPTOR BLOCKING AGENT; RECEPTOR PROTEIN; SERINE DERIVATIVE; THIOL REAGENT; UNCLASSIFIED DRUG; CHLOROMERCURIBENZENESULFONIC ACID; CYCLIC AMP; INOSITOL PHOSPHATE; MEMBRANE PROTEIN; P2RY12 PROTEIN, HUMAN; PRIMER DNA; PURINE P2 RECEPTOR; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR; RECOMBINANT PROTEIN; THIOL DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CHO CELL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISULFIDE BOND; DOSE RESPONSE; EMBRYO; ENZYME INHIBITION; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; IC 50; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; BIOSYNTHESIS; CHEMISTRY; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; HAMSTER; KINETICS; METABOLISM; MOLECULAR GENETICS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

4-CHLOROMERCURIBENZENESULFONATE; ADENOSINE DIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BINDING SITES; CHO CELLS; CRICETINAE; CYCLIC AMP; CYSTEINE; DNA PRIMERS; HUMANS; INOSITOL PHOSPHATES; KINETICS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; RECEPTORS, PURINERGIC P2; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SULFHYDRYL COMPOUNDS; TRANSFECTION;

EID: 0037588974     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3027     Document Type: Article

References (45)

1. Burnstock G. A basis for distinguishing two types of purinergic receptors. In: Straub RW, Bolis L, eds. Cell Membrane Receptors for Drugs and Hormones: a Multidisciplinary Approach. New York, NY: Raven Press; 1978:107-118.
2. Gordon J. Extracellular ATP: effects, sources and fates. Biochem J. 1986;233:309-319.
3. Fredholm BB, Abbracchio MP, Burnstock G, et al. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci. 1997;18:79-82.
4. Zhang FL, Luo L, Gustafson E, et al. P2Y(13): identification and characterization of a novel Galphai-coupled ADP receptor from human and mouse. J Pharmacol Exp Ther. 2002;301:705-713.
5. Communi D, Govaerts C, Parmentier M, Boeynaems J-M. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem. 1997;272:31969-31973.
6. Communi D, Gonzalez NS, Detheux M, et al. Identification of a novel human ADP receptor coupled to G(i). J Biol Chem. 2001;276:41479-41485.
7. Zhang FL, Luo L, Gustafson E, et al. ADP is the cognate ligand for the orphan G-protein coupled receptor SP1999. J Biol Chem. 2001;276:8608-8615.
8. Hollopeter J, Jantzen H-M, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202-207.
9. Kunapuli SP. Multiple P2 receptor subtypes on platelets: a new interpretation of their function. Trends Pharmacol Sci. 1998;19:391-394.
10. Boyer JL, Lazarowski ER, Chen X-H, Harden TK. Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase. J Pharmacol Exp Ther. 1993;267:1140-1146.
11. Planet I, Merle M, Labouesse J. ADP and, indirectly, ATP are potent inhibitors of cAMP production in intact isopreterenol-stimulated C6 glioma cells. Biochem Biophys Res Commun. 1989;163:1150-1157.
12. Feolde E, Vigne P, Breittmayer JP, Frelin C. ATP, a partial agonist of atypical P2y purinoceptors in rat brain capillary endothelial cells. Brit J Pharmacol. 1995;115:1199-1203.
13. Ayyanathan K, Webb TE, Sandhu AK, Athwal RS, Barnard EA, Kunapuli SP. Cloning and chromosomal localization of human P2Y1 purinoceptor. Biochem Biophys Res Commun. 1996;218:783-788.
14. Ayyanathan K, Naylor SL, Kunapuli SP. Structural characterization and fine chromosomal mapping of the human P2Y1 purinergic receptor gene (P2YR1). Som Cell Mol Genet. 1996;22:419-424.
15. Fabre JE, Nguyen M, Latour A, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999;5:1199-1202.
16. Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001;107:1591-1598.
17. Vigne P, Hechler B, Gachet C, Breittmayer JP, Frelin C. Benzoyl ATP is an antagonist of rat and human P2Y1 receptors and of platelet aggregation. Biochem Biophys Res Commun. 1999;256:94-97.
18. Hourani SMO, Hall DA. Receptors for ADP on human platelets. Trends in Pharmacol Sci. 1994;15:103-108.
19. Kunapuli SP. Molecular physiology of platelet ADP receptors. Drug Dev Res. 1998;45:135-139.
20. Mills DCB. ADP receptor in platelets. Thromb Haemost. 1996;76:835-856.
21. Bennett JS. Novel platelet inhibitors. Annu Rev Med. 2001;52:161-184.
22. 12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun. 2001;283:379-383.
23. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891-896.
24. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129:1439-1446.
25. Sugidachi A, Asai F, Yoneda K, et al. Antiplatelet action of R-99224, an active metaboiite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacoi. 2001;132:47-54.
26. Rao AK, Kowalska MA. ADP-induced platelet shape change and mobilization of cytoplasmic ionized calcium are mediated by distinct binding sites on platelets: 5′-p-fluorosulfonylbenzoyladenosine is a weak platelet agonist. Blood. 1987;70:751-756.
27. Cristalli G, Mills DCB. Identification of a receptor for ADP on blood platelets by photoaffinity labelling. Biochem J. 1993;291:875-881.
28. Cook JV, Eidne KA. An intramolecular disulfide bond between conserved extracellular cysteines in the gonadotropin-releasing hormone receptor is essential for binding and activation. Endocrinology. 1997;138:2800-2806.
29. D'Angelo DD, Eubank JJ, Davis MG, Dorn GW II. Mutagenic analysis of platelet thromboxane receptor cysteines: roles in ligand binding and receptor-effector coupling. J Biol Chem. 1996;271:6233-6240.
30. Ji TH, Grossmann M, Ji I. G protein-coupled receptors: I. Diversity of receptor-ligand interactions. J Biol Chem. 1998;273:17299-17302.
31. Hoffmann C, Moro S, Nicholas RA, Harden TK, Jacobson KA. The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. J Biol Chem. 1999;274:14639-14647.
32. Jin J, Tomlinson W, Kirk IP, Kim YB, Humphries RG, Kunapuli SP. The C6-2B glioma cell P2Y(AC) receptor is pharmacologically and molecularly identical to the platelet P2Y(12) receptor. Br J Pharmacol. 2001;133:521-528.
33. Akbar GKM, Dasari VR, Webb TE, et al. Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells. J Biol Chem. 1996;271:18363-18367.
34. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation: I. Evidence for three distinct ADP receptors on platelets. J Biol Chem. 1998;273:2024-2029.
35. Kunapuli P, Lawson JA, Rokach J, Fitzgerald GA. Functionai characterization of the ocular prostaglandin F2α (PGF2α) receptor: activation by the isoprostane, 12-iso-PGF2α. J Biol Chem. 1997;272:27147-27154.
36. Filtz TM, Li Q, Boyer JL, Nicholas RA, Harden TK. Expression of a cloned P2y purinergic receptor that couples to phospholipase C. Mol Pharmacol. 1994;46:8-14.
37. Leon C, Hechler B, Freund M, et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice [see comments]. J Clin Invest. 1999;104:1731-1737.
38. Mills DCB, Puri RN, Hu C-J, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Atheroscler Thromb. 1992;12:430-436.
39. Geiger J, Brich J, Honig-Liedl P, et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol. 1999;19:2007-2011.
40. Jin J, Kunapuli SP. Co-activation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U. S. A. 1998;95:8070-8074.
41. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet aggregation characterized by severe impairment of platelet responses to adenosine 5′-diphosphate. Blood. 1992;80:2787-2796.
42. Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol. 2000;20:E101-E106.
43. Nurden P, Savi P, Heilmann E, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest. 1995;95:1612-1622.
44. Seyfarth HJ, Koksch M, Roethig G, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J. 2002;143:118-123.
45. Gachet C, Stierle A, Cazenave JP, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol. 1990;40:229-238.